menu

Investors & Media

Press Releases

Press Releases

Keyword Search

Nov 11, 2023
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
Nov 09, 2023
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
Nov 03, 2023
Ionis to present at upcoming investor conferences
Nov 02, 2023
Ionis reports third quarter 2023 financial results
Oct 19, 2023
Ionis to hold third quarter 2023 financial results webcast
Oct 04, 2023
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
Sep 28, 2023
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
Sep 27, 2023
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
Sep 26, 2023
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
Sep 12, 2023
Ionis to host investor and analyst day event
Aug 30, 2023
Ionis to present at upcoming investor conferences
Aug 09, 2023
Ionis reports second quarter 2023 financial results
Aug 03, 2023
Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease
Jul 31, 2023
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
Jul 28, 2023
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
Jul 26, 2023
Ionis to hold second quarter 2023 financial results webcast
Jul 10, 2023
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
Jul 05, 2023
Ionis to present at upcoming investor conference
Jun 30, 2023
New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
Jun 08, 2023
Ionis prices private placement of convertible senior notes
Jun 06, 2023
Ionis announces proposed private placement of convertible notes
Jun 01, 2023
Ionis announces positive donidalorsen late-stage clinical progress in HAE
May 10, 2023
Ionis to host 2023 virtual Annual Meeting of Stockholders
May 09, 2023
Ionis to present at upcoming investor conferences
May 03, 2023
Ionis reports first quarter 2023 financial results
Apr 25, 2023
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
Apr 24, 2023
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
Apr 20, 2023
Ionis to hold first quarter 2023 financial results webcast
Mar 29, 2023
New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
Mar 28, 2023
Ionis to present at upcoming investor conferences
Mar 27, 2023
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
Mar 22, 2023
Ionis announced FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS
Mar 07, 2023
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Feb 28, 2023
Ionis to present at upcoming investor conferences
Feb 22, 2023
Ionis reports fourth quarter and full year 2022 financial results
Feb 21, 2023
Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
Feb 08, 2023
Ionis to hold fourth quarter and full year 2022 financial results webcast
Feb 01, 2023
Ionis announces GSK has advanced bepirovirsen into Phase 3 development
Jan 31, 2023
Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
Jan 26, 2023
Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research
Jan 09, 2023
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
Jan 04, 2023
Ionis to present at 41st Annual J.P. Morgan Healthcare conference
Load More »